| Metric | Value | Source/Year |
|---|---|---|
| Global age-standardized DALY rate (ASR-DALYs) | 24.74 per 100,000 | GBD-based global analysis, 2021 (pqac-00000043, pqac-00000044) |
| Global age-standardized death rate (ASDR) | 0.86 per 100,000 | GBD-based global analysis, 2021 (pqac-00000043, pqac-00000044) |
| US annual cases | 52,000-70,000 estimated annually; 10,000 reported cases in 2018 | US epidemiology summaries/reviews (pqac-00000001, pqac-00000004) |
| EU/EEA notification rate | 2.2 per 100,000 in 2018-2019; up from 1.2-1.4 per 100,000 in 2012-2016 | EU/EEA surveillance analysis, 2023 (pqac-00000004) |
| Overall mortality rate | 7-10% overall | Recent reviews, 2024 (pqac-00000003, pqac-00000005) |
| Mortality in severe/ICU cases | Up to 40% | Severe Legionnaires’ disease review, 2024 (pqac-00000005, pqac-00000019) |
| Swiss incidence trend | Increased from 1.1 to 5.6 per 100,000 between 2000 and 2020 | Global burden study citing Swiss surveillance trend (pqac-00000046) |
| Age group with highest burden | >70 years; 101.85 ASR-DALYs per 100,000 | GBD-based global analysis, 2021 (pqac-00000043) |
| Sex ratio | Male predominance, approximately 2:1 to 3:1 | Epidemiologic reviews and surveillance summaries (pqac-00000005, pqac-00000007) |
| Case fatality in otherwise healthy individuals | ~10% | Review summary (pqac-00000002, pqac-00000022) |
| Case fatality in high-risk patients | >25% | Review summary for elderly, smokers, immunocompromised, and comorbid patients (pqac-00000002, pqac-00000022) |
| ICU admission rate | Approximately one-third of cases | Severe Legionnaires’ disease review, 2024 (pqac-00000005) |
| Annual treatment costs in the US | >$340 million | US epidemiology/economic burden summary (pqac-00000004) |


*Table: This table summarizes the most relevant recent epidemiology and global burden metrics for Legionnaires' disease, including incidence, mortality, healthcare burden, and age-stratified risk. It is useful as a compact reference for disease knowledge base population and comparative public health assessment.*